Ashmore shares fall 1.6% despite profit jump as underlying earnings weaken

Ashmore's annual profit attributable rose 27% to £103.3 million, narrowly above the £102.9 million consensus, but shares fell 1.56% to 215p as weaker performance fees pressured underlying earnings. Adjusted EBITDA declined 32% to £35.7 million and adjusted diluted EPS fell 29% to 5.0p, while performance fees dropped to £1.4 million from £10.2 million. AuM increased 13% to $54.0 billion on $2.7 billion of net inflows and $3.7 billion of investment gains, though it was modestly below the roughly $54.6 billion consensus estimate.

Analysis

ASHM’s issue is earnings quality rather than headline profitability: investment-mark gains have masked deterioration in the recurring fee-and-margin engine. In an asset manager, this matters disproportionately because compensation and fixed distribution costs create negative operating leverage when variable revenue is weak; absent a meaningful recovery in incentive fees, incremental AuM will not translate cleanly into EPS. The market is likely discounting that the dividend is being maintained through a cyclical trough, but dividend cover and cash conversion should be the next scrutiny point.

The more important read-through is that a strong EM beta tape has not yet produced commensurate monetization for active EM managers. That favors scalable benchmark, index and analytics providers such as MSCI over stock-picking franchises: MSCI captures asset-allocation growth with substantially less dependence on alpha realization or performance-fee crystallization. A continued EM rally can therefore widen the MSCI/ASHM relative-quality gap over the next 1-3 quarters, unless ASHM demonstrates that inflows are moving into higher-fee equity and blended mandates rather than lower-fee institutional debt products.

Contrarianly, ASHM can rebound sharply if EM allocation shifts from tactical beta into active mandates, particularly if dollar weakness and easing global real rates broaden returns beyond the largest EM equity markets. That is a 6-18 month scenario, not a reason to chase near-term weakness: the thesis is falsified if quarterly net flows reverse, management-fee yield declines further, or the next reporting period again requires seed-capital gains to support reported profit.

Key Decisions for Investors

• Maintain/establish a 3-month relative-value position: long MSCI / short ASHM in equal beta-adjusted notional. The trade expresses EM allocation growth with lower operating-risk exposure; reassess if ASHM reports accelerating management-fee revenue and a material performance-fee recovery.
• Avoid adding ASHM solely on the dividend or reported profit beat. Require evidence in the next quarterly AuM update that net flows persist and fee yield stabilizes; without that, downside remains tied to renewed EM volatility and further earnings-estimate cuts.
• For existing ASHM longs, use any near-term EM-risk rally to reduce exposure unless the company quantifies higher-fee mandate wins. A break in the broad EM equity trend or a stronger dollar would likely pressure both AuM and investor appetite within days to weeks.
• Watch MSCI’s EM-linked asset-based fees and ETF/benchmark licensing commentary at its next earnings release. Positive EM asset-growth disclosure supports adding to MSCI; weak asset-based fee growth would weaken the relative-value thesis even if ASHM remains operationally challenged.